Governments have decided they will pay any price in the fight against COVID-19 while the pharmaceutical sector is already grappling with supply. Nobody should expect the PBS in 2021, 2022 or beyond to look like it does in 2020 - and that is before you even consider the long-term budgetary impact of the shock about to hit the economy.
This is just the start of a challenge that will almost certainly leave a permanent 'scar'
March 21, 2020 Latest NewsComment
Latest Video
New Stories
-
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News -
Parsimony has unfortunately become an enduring test of the institution's legitimacy
December 20, 2025 - - Latest News -
PBAC delivers a broad range of outcomes in November, including for obesity
December 20, 2025 - - Latest News -
Takeda’s next-generation psoriasis therapy delivers landmark Phase 3 results
December 19, 2025 - - Latest News -
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech

